Streamlining market access to advanced therapies: What can we learn from global models?
Tracks
Track 3
| Friday, November 1, 2024 |
| 10:30 AM - 11:15 AM |
Details
Around the world there are different approaches to health technology assessment, regulatory approvals and reimbursement pathways. Streamlining market access for cell and gene therapies is essential and Australia’s current systems were not established for these advanced therapies. This session will ask what Australia can learn from models around the world. Sustainable market access pathways will accelerate the cell and gene industry’s growth, enable health system readiness, create job opportunities and ensure everyone in Australia has access to these advanced therapies.
Speaker
Jane Adams
Associate Director Market Access
Novartis
Panellist
Warwick Shaw
Rare Diseases Advisory Group
Medicines Australia
Chair
